Joint Statement from Leading HIV/AIDS and Viral Hepatitis Advocates regarding Manufacturer Action on the 340B Drug Pricing Program
A group of six leading HIV/AIDS and viral hepatitis advocates today released the following joint statement regarding recent manufacturer action against the 340B Drug Pricing Program: